Journal of Diabetes and Its Complications
Volume 19, Issue 6 , Pages 356-360 , November 2005

Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals

Received 21 December 2004 ,Revised 8 April 2005 ,Accepted 3 May 2005.

References 

  1. Bruce DG, Chisholmn DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early postprandial insulin secretion in non-insulin-diabetes. Diabetes. 1988;37:736–744
  2. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. American Journal of Physiology. 1979;237:E214–E223
  3. Del Prato S. Metabolic control in Type 2 diabetes: The impact of prandial glucose. Current Opinion in Endocrinology & Diabetes. 1999;6(Suppl. 1):S1–S6
  4. Del Prato S, Hene RJ, Kelson L, Guitard C, Shen SG, Emmons RP. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care. 2003;26:2075–2080
  5. Dunn CJ, Faulds D. Nateglinide. Drugs. 2000;60:607–617
  6. Dunning BE. New non-sulfonylurea insulin secretagogues. Expert Opinion on Investigational Drugs. 1997;6:1041–1048
  7. Ferrannini E, Mari A. How to measure insulin sensitivity. Journal of Hypertension. 1998;16:885–886
  8. Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care. 2003;26:1685–1690
  9. Fujitani S, Yada T. A novel d-phenylalanine-derived agent A-4166 increases cytosolic free C++ in rat pancreatic β-cells by stimulating Ca ++ influx. Endocrinology. 1994;134:1395–1400
  10. Ikenoue T, Akiyoshi M, Fujitani S, Okazaki K, Kondo N, Maki T. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (−)-N-(trans-4-isopropylcyclohexane-carbonyl)-d-phenylalanine (A-4166). British Journal of Pharmacology. 1997;120:137–145
  11. Jeyaseelan L, Rao PS. Methods of determining sample sizes in clinical trials. Indian Pediatrics. 1989;29:115–121
  12. Johnson DG, Bressler R. New pharmacologic approaches. In:  Porte D,  Sherwin RS editor. Diabetes mellitus. 5th ed.. Stanford: Connecticut, Appleton & Lange; 1997;p. 1293–1305
  13. Kelley D. Approaches to preventing prandial hyperglycemic excursions. Current Opinion in Endocrinology & Diabetes. 1999;6(Suppl. 1):S7–S11
  14. Morimoto S, Mokuda O, Sakamoto Y. AY-4166 increase the sensitivity of insulin secretion to glucose in insolated perfused rat pancreas. Hormone and Metabolic Research. 1998;30:77–79
  15. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 2001;44:929–945
  16. Raskin P, Klafe L, McGill J, et al. Efficacy and safety of combination therapy. Repaglinide plus metformin versus nateglinida plus metformin. Diabetes Care. 2003;26:2063–2068
  17. Saloranta C, Guitard C, Pecher E, et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care. 2002;25:2141–2149
  18. Sato Y, Nishikawa M, Shinkai H, Sukegawa E. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropycyclohexyl)-carbonyl]-d-phenylalanine (A-4166) and its stimulatory effect on insulin secretion in animals. Diabetes Research and Clinical Practice. 1991;12:58–59
  19. Sato Y, Nishikawa M, Shinkai H, Sukegawa E. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carboxyl]-d-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Research and Clinical Practice. 1991;12:53–59
  20. Shinkai H, Nishikawa M, Sato Y, et al. N-(cyclohexylcarbonyl)-d-phenylalanines and related compounds. A new class of oral hypoglycemic agents. Journal of Medicinal Chemistry. 1989;32:1436–1441
  21. Shinkai H, Toi K, Kumashiro I, et al. N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents. Journal of Medicinal Chemistry. 1988;31:2092–2097
  22. Walter YH, Spratt DI, Garreffa S, McLead JF. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus. European Journal of Clinical Pharmacology. 2000;58:129–133

PII: S1056-8727(05)00046-2

doi: 10.1016/j.jdiacomp.2005.05.004

Journal of Diabetes and Its Complications
Volume 19, Issue 6 , Pages 356-360 , November 2005

Article Tools

* Image Usage & Resolution